CLASSYS Inc. – Trademark Portfolio
Entity Type: 03
CLASSYS Inc. holds 55 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 34 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 6 Nice Classification classes. Currently, 25 trademarks are registered and 9 are pending. Notable registered marks include CURAS, CLATUU, ILOODA, REEPOT, and SCIZER.
(CLASSYS, Yeoksam-dong),
208. Teheran-ro, Gangnam-gu, Seoul
Showing of trademarks Trademarks
Trademark Classifications
CLASSYS Inc.'s trademark portfolio spans 6 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does CLASSYS Inc. have?
CLASSYS Inc. has 55 U.S. trademarks filed with the USPTO. Of these, 25 registered, 9 pending, 7 abandoned, 1 cancelled.
What trademark classes does CLASSYS Inc. file in?
CLASSYS Inc. files trademarks across 6 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 3 (Cosmetics & Cleaning), Class 44 (Medical Services), Class 21 (Housewares), Class 37 (Building & Construction). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are CLASSYS Inc.'s most well-known trademarks?
CLASSYS Inc.'s registered trademark portfolio includes well-known marks such as CURAS, CLATUU, ILOODA, REEPOT, and SCIZER. These are among 25 currently registered trademarks in the portfolio.
What is CLASSYS Inc.'s trademark registration success rate?
CLASSYS Inc. has a 76% trademark registration rate, with 25 out of 33 resolved applications resulting in successful registration. Currently, 9 applications are pending review.